Skip to main content

Information about available vaccines



From the beginning of the pandemic, the tremendous effort of all scientists worldwide has been made to develop a safe vaccine against the new coronavirus. To ensure maximal safety, only EU-approved vaccines are allowed for usage in the Czech Republic (more about the vaccine approval process can be found in Related Links).

Covid-19 vaccines are drugs that prevent the disease caused by the new SARS-CoV-2 coronavirus by inducing an immune response against the virus. Simply put, the vaccine teaches the body where the virus's weakness is and how to trigger the appropriate immune response so that the immunity kills the virus before it can reproduce.

Five of the existing vaccines are registered in the EU so far. 

Overview of existing vaccines

Vaccines approved by EMA for usage within the EU member states:

Name

Holder of the registration 

Indication

(age)

Vaccination scheme

Vaccine type

Comirnaty

Pfizer/BioNTech

from 5 years

Basic vaccination scheme 

Two doses three weeks apart 

Booster dose* 

Adults and adolescents 12 years and older may receive the first booster dose three months after completion of the primary vaccination scheme 

For children aged 5 to 11 years, at least six months after the baseline vaccination

mRNA

Spikevax

Moderna

from 6 years

Basic vaccination scheme 

Two doses 28 days apart 

Booster dose* 

Adults and adolescents 12 years and older may receive the first booster dose three months after completing the primary vaccination scheme. A half dose is used to administer the booster dose

mRNA

Vaxzevria

AstraZeneca

from 18 years

Basic vaccination scheme 

two doses four up to 12 weeks apart

vector 

JCOVDEN

Janssen (Johnson&Johnson)

from 18 years

Basic vaccination scheme 

One dose

Booster dose* 

A booster dose (second dose) may be administered intramuscularly at least two months after primary vaccination in individuals 18 years of age and older

vector

Nuvaxovid

Novavax

from 12 years

Basic vaccination scheme 

two doses 21 days apart. 

Booster dose* 

The booster dose may be given at least six months after the primary vaccination in individuals aged 18 years and older

protein-based 

Comirnaty Original/ 

Omicron BA.1 

Pfizer/BioNTech

from 12 years 

 

Intended only for re-vaccination after completion of primary vaccination!!!

A booster dose of Comirnaty Original/Omicron BA.1 (30 micrograms) may be administered to persons aged 12 years and older at least three months after the baseline vaccination or booster dose of COVID-19.

 

mRNA

Spikevax bivalent Original/Omicron BA.1

Moderna

from 12 years

Intended only for re-vaccination after completion of primary vaccination!!!

The booster dose of Spikevax bivalent Original/Omicron BA.1 may be administered to adults and adolescents aged 12 years and older at least three months after the baseline vaccination or booster dose of COVID-19.

 

mRNA

Comirnaty Original/ 

Omicron BA.4-5 

Pfizer/BioNTech

from 6 years

Intended only for re-vaccination after completion of primary vaccination!!!

A booster dose of Comirnaty Original/Omicron BA.4-5 (30 micrograms) may be administered to persons aged 12 years and older at least three months after the baseline vaccination or booster dose of COVID-19.

mRNA

Spikevax bivalent Original/Omicron BA.4-5

Moderna

From 12 years

Intended only for re-vaccination after completion of primary vaccination!!!

The booster dose of Spikevax bivalent Original/Omicron BA.4-5 may be administered to adults and adolescents aged 12 years and older at least three months after the baseline vaccination or booster dose of COVID-19.

mRNA

*Does not include the possibility of combining vaccines; the intervals correspond to those indicated in the summary of product characteristics when the same vaccine is administered

Vaccine

SPC

Medical overview

Comirnaty

Comirnaty, INN-tozinameran, tozinameran/riltozinameran, tozinameran/famtozinameran (europa.eu)

Comirnaty, INN-tozinameran, tozinameran/riltozinameran (europa.eu) 

Spikevax

Spikevax, INN-elasomeran/imelasomeran (europa.eu) 

Spikevax, INN-elasomeran/imelasomeran (europa.eu) 

Nuvaxovid

Nuvaxovid, INN-COVID-19 Vaccine (recombinant, adjuvanted) (europa.eu) 

Nuvaxovid, INN-COVID-19 Vaccine (recombinant, adjuvanted) (europa.eu)

Vaxzevria

Vaxzevria, COVID-19 Vaccine (ChAdOx1-S [recombinant]) (europa.eu)

Vaxevria, COVID-19 Vaccine (ChAdOx1-S [recombinant]) (europa.eu)

 

 

Frequent questions about this topic

How did they manage to produce the vaccines in a year?